# Satellos Bioscience Satellos Bioscience is an Asset Manager based in Toronto, Canada. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Toronto, Canada - **Region:** North America - **Address:** Toronto, Ontario, Canada - **Founded:** 2018 - **Assets under management:** Undisclosed - **Website:** satellos.com ## Regulatory record - **Reports private funds:** No ## About Satellos Bioscience was co-founded in 2018 by Michael Rudnicki, a senior scientist at the Ottawa Hospital Research Institute, and pharmaceutical executive Frank Gleeson. The company's intellectual core is Rudnicki's research into satellite stem cells and their role in muscle regeneration. His lab identified the loss of cell polarity as a fundamental mechanism impairing muscle repair in Duchenne muscular dystrophy, forming the basis for a drug-discovery platform distinct from standard gene therapies or exon-skipping approaches. The firm trades on the TSX Venture Exchange under the symbol MSCL. The company's discovery engine, MyoReGenX, screens for small-molecule drugs that restore asymmetric division to muscle stem cells. Its lead candidate, SAT-3247, is an oral small molecule designed to target the scaffold protein that anchors polarity complexes. Unlike the established genetic-medicine field for Duchenne, which is dominated by Sarepta, Pfizer, and Roche, Satellos is pursuing a mechanism-agnostic pharmacological strategy that does not correct the dystrophin gene itself but aims to enable muscle repair pathways to function despite its absence. The firm has not disclosed a deployment figure, operating with a burn rate typical of a preclinical-stage public biotech. In 2023, it presented preclinical data at the World Muscle Society Congress showing improved muscle function in dystrophic mouse models. Satellos maintains a lean corporate structure with core scientific leadership in Ottawa and corporate operations in Toronto. Rudnicki continues to direct his academic lab alongside his role as Chief Scientific Officer, a dual appointment that shapes the company's scientific culture. In early 2024, the company completed a public offering raising gross proceeds of approximately C$10 million to advance SAT-3247 toward a planned Phase 1 clinical trial. The firm has not disclosed interest in adjacent therapeutic areas beyond muscular dystrophy, focusing its small-molecule platform on a single disease pathway. Satellos operates at the intersection of academic discovery and public-market biotech financing, a hybrid structure that surfaces its science early to public investors. Most preclinical muscle-disease competitors remain venture-backed through Phase 1 or beyond, while Satellos has been public since a reverse takeover in 2020. This capital-market posture means its clinical milestones — particularly the planned healthy-volunteer MAD study for SAT-3247 — will be tested with the liquidity-premium and disclosure requirements of a Canadian-listed stock rather than a private boardroom. ## Sectors - Digital Health - Healthcare Services ## People - Frank Gleeson — President and CEO - Michael Rudnicki — Co-Founder and Chief Scientific Officer ## Questions ### What is Satellos Bioscience's therapeutic approach to Duchenne muscular dystrophy? Satellos targets muscle stem cell polarity rather than the dystrophin gene itself. Co-founder Michael Rudnicki's lab demonstrated that in Duchenne, satellite stem cells lose the ability to divide asymmetrically, crippling muscle repair. SAT-3247, an oral small molecule, is designed to restore that polarity by drugging a scaffold protein, a mechanism distinct from gene therapy, exon skipping, or gene editing. ### Who runs the scientific strategy at Satellos? Dr. Michael Rudnicki, a co-founder, serves as Chief Scientific Officer while maintaining his academic laboratory at the Ottawa Hospital Research Institute. He is widely credited with discovering the role of satellite stem cells in adult muscle regeneration. CEO Frank Gleeson handles corporate and capital-markets execution. ### Is Satellos a public or private company? Satellos Bioscience is a publicly traded company. It listed on the TSX Venture Exchange in 2020 via a reverse takeover of a capital-pool company and trades under the symbol MSCL. The firm has used public equity raises to fund preclinical development of its lead candidate. ### What stage of development is Satellos's lead program in? As of mid-2024, SAT-3247 is in preclinical development. The company has presented animal efficacy data at scientific meetings and raised capital intending to advance the program into Phase 1 human clinical trials. The first trial is expected to be a multiple-ascending-dose study in healthy volunteers. ## Related profiles - [Western Asset Municipal High Income Fund](https://altss.com/profile/western-asset-municipal-high-income-fund-inc) - [Embassy Bancorp](https://altss.com/profile/embassy-bancorp-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/satellos-bioscience-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology